Promising Clinical Trials in Neurodegenerative Diseases

📖 Wiki Page

therapeutic1413 wordssynced 2026-04-02

Promising Clinical Trials in Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Promising Clinical Trials in Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Name</td>
<td>Promising Clinical Trials in Neurodegenerative Diseases</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Overview

flowchart TD Promising_Clinical_Trials_in_N["Promising Clinical Trials in Neurodegenerative D"] Promising_Clinical_Trials_in_N["Neurodegenerative"] Promising_Clinical_Trials_in_N -->|"related to"| Promising_Clinical_Trials_in_N style Promising_Clinical_Trials_in_N fill:#81c784,stroke:#333,color:#000 Promising_Clinical_Trials_in_N["Introduction"] Promising_Clinical_Trials_in_N -->|"related to"| Promising_Clinical_Trials_in_N style Promising_Clinical_Trials_in_N fill:#81c784,stroke:#333,color:#000 Promising_Clinical_Trials_in_N["table"] Promising_Clinical_Trials_in_N -->|"related to"| Promising_Clinical_Trials_in_N style Promising_Clinical_Trials_in_N fill:#81c784,stroke:#333,color:#000 style Promising_Clinical_Trials_in_N fill:#4fc3f7,stroke:#333,color:#000

...

Promising Clinical Trials in Neurodegenerative Diseases

Introduction

Overview

Mermaid diagram (expand to render)

This page summarizes notable ongoing and recent clinical trials for Alzheimer's disease, Parkinson's disease, ALS, frontotemporal dementia, Huntington's disease, and other neurodegenerative conditions. These trials represent the most advanced disease-modifying and neuroprotective approaches in the field. [@van2023]

Alzheimer's Disease

Disease-Modifying Therapies

Lecanemab (Leqembi)

Target: Amyloid-beta protofibrils
Phase: FDA Approved (2023)
Company: Eisai/Biogen
Mechanism: Monoclonal antibody targeting [Aβ](/proteins/amyloid-beta) protofibrils
Status: First disease-modifying therapy with Phase 3 success
Trial: CLARITY-AD (NCT03887455)
Results: 27% slowing of clinical decline (CDR-SB)
Key Findings: Significant reduction in amyloid PET centiloids, slowed [tau](/proteins/tau) accumulation
Safety: ARIA-E (brain edema) in 12.6%, ARIA-H (microhemorrhages) in 17.3%

Donanemab (Kisunla)

Target: N3pG [amyloid-beta](/proteins/amyloid-beta) plaques
Phase: FDA Approved (2024)
Company: Eli Lilly
Trial: TRAILBLAZER-ALZ 2 (NCT04437511)
Results: 35% slowing of decline in patients with low-to-medium tau
Key Findings: Amyloid clearance achieved in majority of patients
Safety: ARIA-E in 24% of patients, three deaths related to ARIA

Simufilam (CT1812)

Target: Amyloid-beta oligomer antagonist
Company: Cognition Therapeutics
Phase: Phase 2/3
Trial: NCT04932265 (SEQUEL)
Mechanism: Prevents Aβ oligomer binding to synaptic receptors
Status: Ongoing, results expected 2026

Blarcamesine (ANAVEX2-73)

Target: Sigma-1 receptor agonist
Company: Anavex
Phase: Phase 2/3
Trial: NCT03790709 (ANAVEX)
Mechanism: Sigma-1 receptor activation promotes neuroprotection, reduces ER stress
Status: Results pending, early signals showed cognitive improvement

Immunotherapy Approaches

ACI-35.40 (Lipid-based Tau Vaccine)

Target: Phospho-tau (Ser396/404)
Company: AC Immune/Janssen
Phase: Phase 1b/2a
Status: Safety and immunogenicity demonstrated
Mechanism: Lipid nanoparticle delivery of phospho-tau antigens

ABBV-8E12 (Tilavonemab)

Target: [Tau](/proteins/tau) protein
Company: AbbVie
Phase: Phase 2 (ABB-RD-02)
Trial: NCT03712787
Status: Ongoing

Semorinemab

Target: Tau antibody
Company: Genentech/Roche
Phase: Phase 2 (LAURIET)
Results: Did not meet primary endpoint in mild cognitive impairment

Neuroprotective Approaches

Lithium Carbonate

Target: [GSK-3β](/entities/gsk3-beta) inhibition
Phase: Phase 2/3
Trials: NCT00088387, NCT02068560
Status: Mixed results, ongoing studies in responders

Variglcit (Varoglit)

Target: AMPK activator
Company: Vivoryon
Phase: Phase 2
Mechanism: Activates AMPK, reduces tau phosphorylation
Status: Completed, signals of cognitive benefit

Parkinson's Disease

Disease-Modifying Therapies

BIIB122 (DNL151)

Target: LRRK2 kinase inhibitor
Company: Biogen/Denali
Phase: Phase 2b (LUMA)
Trial: NCT05348785
Status: Recruiting
Rationale: LRRK2 mutations are common in familial PD, kinase hyperactivity in sporadic PD

AAV2-AADC (VY-AADC01)

Target: Gene therapy for aromatic L-amino acid decarboxylase
Company: Voyager Therapeutics
Phase: Phase 1/2
Trial: NCT03562494
Status: Long-term benefits observed up to 5 years
Mechanism: Restores dopamine synthesis in putamen

Prasinezumab (RO7046015)

Target: [Alpha-synuclein](/proteins/alpha-synuclein) antibody
Company: Roche
Phase: Phase 2 (PASADENA)
Results: Primary endpoint not met, follow-up showed slowing of motor progression

Cinpanemab (BIIB054)

Target: Alpha-synuclein antibody
Company: Biogen
Phase: Phase 2 (SPARK)
Results: Did not meet primary endpoint

Neuroprotective and Symptomatic

Inosine (SURE-PD3)

Target: Urate elevation
Phase: Phase 3
Status: Primary endpoint not met, post-hoc analysis showed benefit in higher urate

Azilect (rasagiline)

Target: MAO-B inhibition
Phase: Phase 4
Status: Disease-modifying signals in post-hoc analysis (ADAGIO)

Ampreloxetine (TD-9855)

Target: Norepinephrine transporter inhibitor
Company: Theravance
Phase: Phase 3 (STEP-HF)
Status: Orthostatic hypotension in PD

Amyotrophic Lateral Sclerosis

Approved Therapies

Tofersen (Qalsody)

Target: SOD1 gene/mRNA
Company: Biogen/Ionis
Status: FDA approved 2023
Trial: VALOR (NCT02623699) and open-label extension
Results: Reduced SOD1 protein, slowed functional decline in SOD1 patients
Mechanism: Antisense oligonucleotide reducing SOD1 production

Relyvrio (Albrioza/Sodium phenylbutyrate-taurursodiol)

Target: Mitochondrial dysfunction and ER stress
Company: Amylyx
Status: FDA approved 2022 (withdrawn 2024)
Trial: CENTAUR (NCT03021501)
Results: Survival benefit, slower functional decline
Note: Voluntarily withdrawn from market in 2024 after Phase 3 failure

In Development

CNM-Au8 (Gold nanocrystals)

Target: Catalase mimetic, mitochondrial function
Company: Clene Nanomedicine
Phase: Phase 2/3 (HEALEY ALS Platform Trial)
Status: Ongoing
Results: Survival signal in preliminary analysis

Reldeso (ATXN2 ASO)

Target: ATXN2 gene silencing
Company: Biogen/Ionis
Phase: Phase 1/2
Rationale: ATXN2 intermediate repeats increase ALS risk

Mesenchymal Stem Cells

Target: Neuroprotection, immunomodulation
Phase: Various trials ongoing
Company: Various

Gene Therapy Approaches

AAV9-SOD1: Gene silencing for SOD1 ALS
AAV9-FUS: Gene silencing for FUS ALS
Antisense oligonucleotides: Multiple targets in development

Frontotemporal Dementia

Progranulin Modulators

AL001 (Litifilimab)

Target: Progranulin modulator
Company: Alector
Phase: Phase 2/3 (INFRONT-2)
Trial: NCT03987295
Status: Received Fast Track designation
Rationale: Progranulin deficiency causes ~10-20% of FTD

Tau-Targeted Therapies

ABBV-8E12 (Tilavonemab)

Target: Tau antibody
Company: AbbVie
Phase: Phase 2
Trial: NCT03712787

JNJ-63733657

Target: Tau antibody
Company: Janssen
Phase: Phase 1
Status: Completed

Huntington's Disease

Huntingtin-Lowering Approaches

Tominersen (RG6049)

Target: [Huntingtin](/proteins/huntingtin-protein) mRNA
Company: Roche/Ionis
Phase: Phase 3 (GENERATION HD1)
Status: Trial discontinued (negative results at high dose)
New Approach: Lower-dose trial (GENERATION HD2) planned

other ASOs in Development

Wave Life Sciences: Allele-selective ASOs targeting mutant [huntingtin](/genes/htt)
PTC518: Oral ASO in development

Neuroprotective Approaches

Pridopidine

Target: Sigma-1 receptor agonist
Company: Prilenia
Phase: Phase 2/3 (PROOF-HD)
Status: Mixed results, signal in functional measures

VX-809 (Lumacaftor)

Target: CFTR corrector (protein folding)
Company: Vertex
Rationale: May help mutant huntingtin folding
Status: Phase 1

Biomarker Trials and Endpoints

Tau PET Imaging

Tracers: Flortaucipir (AV-1451), MK-6240, PI-2620
Use: Assessing tau burden as surrogate endpoint
Correlation: Strong correlation with clinical outcomes in AD

Neurofilament Light Chain (NfL)

Utility: Blood biomarker for disease progression
Use: Used in multiple trial endpoints
Platforms: Simoa, Elecsys
Clinical utility: FDA cleared for ALS progression monitoring

CSF Biomarkers

Aβ42/tau ratios: Amyloid and tau pathology
Alpha-synuclein seeding assays: Syn-SAA for PD/DLB
p-tau/t-tau ratio: Emerging for AD staging
Emerging: Extracellular vesicles, neuronal damage markers

Genetic Biomarkers

[APOE](/proteins/apoe-protein) status: Response prediction for anti-amyloid therapies
LRRK2 G2019S: PD patient selection
SOD1, FUS, [C9orf72](/entities/c9orf72): ALS genetic stratification

Trial Design Innovations

Master Protocols and Platform Trials

HEALEY ALS Platform Trial: Multiple agents simultaneously
[DIAN](/entities/dian-study): Adaptive trial in dominantly inherited AD
Parkinson's Progression Markers Initiative (PPMI): Observational with trial-ready cohort

Digital Endpoints

Remote monitoring: Continuous data collection
Wearable devices: Motor symptom tracking
[App](/entities/app-protein)-based cognitive testing: Ecological momentary assessment
Voice analysis: Speech markers for progression

Adaptive Designs

Sample size re-estimation: Interim adjustments
Enrichment strategies: Biomarker-based patient selection
Multi-arm designs: Efficient comparison of multiple doses

Regulatory Innovations

Accelerated Approval: Based on surrogate endpoints
Real-world evidence: Post-marketing requirements
Patient-reported outcomes: Increased regulatory acceptance

Future Directions

Combination Therapies

Rationale: Multiple pathological mechanisms require multi-target approaches
Examples: Anti-amyloid + anti-tau, neuroprotection + disease modification
Challenges: Regulatory pathways, safety considerations

Precision Medicine Approaches

Genetic stratification: Population-specific responses
Biomarker-guided: Patient selection based on pathology
Digital phenotyping: Individualized monitoring

Prevention Trials

Preclinical AD: Anti-amyloid in cognitively normal but biomarker-positive
Genetic at-risk: CARMEL (autosomal dominant AD), Generation programs

Background

The study of Promising Clinical Trials In Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@sims2023]

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@miller2023]

Additional evidence sources: [@paganoni2024] [@scheltens2024] [@kwon2024] [@petrov2024] [@cummings2024] [@clinicaltrialsgov2026]

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

External Links

[ClinicalTrials.gov](https://clinicaltrials.gov)
[Alzheimer's Association TrialMatch](https://www.alz.org/)
[Parkinson's Foundation Clinical Trials](https://www.parkinson.org/)
[ALS Clinical Trials](https://www.als.net/)
[CHDI Foundation - Huntington's Disease](https://www.chdi-foundation.org/)

References

[van Dyck CH, et al, (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36449413/))

[Sims JR, et al, (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36951845/))

[Miller T, et al, (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36812418/))

[Paganoni S, et al, (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38231618/))

Scheltens P, et al, (2024) (2024)

Kwon D, et al, (2024) (2024)

Petrov D, et al, (2024) (2024)

Cummings J, et al, (2024) (2024)

Unknown, ClinicalTrials.gov database searches (accessed 2026) (2026)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — 0.59 · Target: APOE
[APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — 0.61 · Target: APOE
[Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — 0.56 · Target: APOE
[Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — 0.55 · Target: APOE, LRP1, LDLR
[Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — 0.51 · Target: APOE
[Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — 0.46 · Target: APOE
[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

Promising Clinical Trials in Neurodegenerative Diseases

Promising Clinical Trials in Neurodegenerative Diseases

Introduction

Overview

Promising Clinical Trials in Neurodegenerative Diseases

Introduction

Overview

Alzheimer's Disease

Disease-Modifying Therapies

Lecanemab (Leqembi)

Donanemab (Kisunla)

Simufilam (CT1812)

Blarcamesine (ANAVEX2-73)

Immunotherapy Approaches

ACI-35.40 (Lipid-based Tau Vaccine)

ABBV-8E12 (Tilavonemab)

Semorinemab

Neuroprotective Approaches

Lithium Carbonate

Variglcit (Varoglit)

Parkinson's Disease

Disease-Modifying Therapies

BIIB122 (DNL151)

AAV2-AADC (VY-AADC01)

Prasinezumab (RO7046015)

Cinpanemab (BIIB054)

Neuroprotective and Symptomatic

Inosine (SURE-PD3)

Azilect (rasagiline)

Ampreloxetine (TD-9855)

Amyotrophic Lateral Sclerosis

Approved Therapies

Tofersen (Qalsody)

Relyvrio (Albrioza/Sodium phenylbutyrate-taurursodiol)

In Development

CNM-Au8 (Gold nanocrystals)

Reldeso (ATXN2 ASO)

Mesenchymal Stem Cells

Gene Therapy Approaches

Frontotemporal Dementia

Progranulin Modulators

AL001 (Litifilimab)

Tau-Targeted Therapies

ABBV-8E12 (Tilavonemab)

JNJ-63733657

Huntington's Disease

Huntingtin-Lowering Approaches

Tominersen (RG6049)

other ASOs in Development

Neuroprotective Approaches

Pridopidine

VX-809 (Lumacaftor)

Biomarker Trials and Endpoints

Tau PET Imaging

Neurofilament Light Chain (NfL)

CSF Biomarkers

Genetic Biomarkers

Trial Design Innovations

Master Protocols and Platform Trials

Digital Endpoints

Adaptive Designs

Regulatory Innovations

Future Directions

Combination Therapies

Precision Medicine Approaches

Prevention Trials

Background

Allen Brain Atlas Resources

See Also

External Links

References

Related Hypotheses